Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies

Abstract

BackgroundEvery year, hundreds of thousands of patients experience treatment failure or adverse drug reactions (ADRs), many of which could be prevented by pharmacogenomic testing. However, the primary knowledge needed for clinical pharmacogenomics is currently dispersed over disparate data structures and captured in unstructured or semi-structured formalizations. This is a source of potential ambiguity and complexity, making it difficult to create reliable information technology systems for enabling clinical pharmacogenomics.MethodsWe developed Web Ontology Language (OWL) ontologies and automated reasoning methodologies to meet the following goals: 1) provide a simple and concise formalism for representing pharmacogenomic knowledge, 2) finde errors and insufficient definitions in pharmacogenomic knowledge bases, 3) automatically assign alleles and phenotypes to patients, 4) match patients to clinically appropriate pharmacogenomic guidelines and clinical decision support messages and 5) facilitate the detection of inconsistencies and overlaps between pharmacogenomic treatment guidelines from different sources. We evaluated different reasoning systems and test our approach with a large collection of publicly available genetic profiles.ResultsOur methodology proved to be a novel and useful choice for representing, analyzing and using pharmacogenomic data. The Genomic Clinical Decision Support (Genomic CDS) ontology represents 336 SNPs with 707 variants; 665 haplotypes related to 43 genes; 22 rules related to drug-response phenotypes; and 308 clinical decision support rules. OWL reasoning identified CDS rules with overlapping target populations but differing treatment recommendations. Only a modest number of clinical decision support rules were triggered for a collection of 943 public genetic profiles. We found significant performance differences across available OWL reasoners.ConclusionsThe ontology-based framework we developed can be used to represent, organize and reason over the growing wealth of pharmacogenomic knowledge, as well as to identify errors, inconsistencies and insufficient definitions in source data sets or individual patient data. Our study highlights both advantages and potential practical issues with such an ontology-based approach.Electronic supplementary materialThe online version of this article (doi:10.1186/s12911-015-0130-1) contains supplementary material, which is available to authorized users.

AgriEnt: A Knowledge-Based Web Platform for Managing Insect Pests of Field Crops

“…To this end, it uses medication profiles, a drug knowledge ontology and the TOPSIS (Technique for Order of Preference by Similarity to Ideal Solution) technique for calculating the ideal solution. In [15], the authors presented an automated reasoning methodology to assign alleles and phenotypes to patients and to match patients to appropriate pharmacogenomic guidelines. This methodology works over ontologies that provide a formal representation of pharmacogenomic knowledge.…”

A fuzzy-ontology-oriented case-based reasoning framework for semantic diabetes diagnosis

“…Samwald et al [32] asserted that the building CDSS system requires the encoding of clinical data by using ontologies. They developed a CDSS for pharmacogenomic knowledge representation and reasoning based on an OWL2 ontology [33]. However, using standard medical ontologies, such as SCT, supports the implementation of semantically intelligent case retrieval algorithms [34], enhances the interoperability and seamlessly integration between CDSS and EHR environment [16], and supports the creation of standard encoded case-base knowledge [35].…”

PGxO: A very lite ontology to reconcile pharmacogenomic knowledge units

“…The PHARE ontology (for PHArmacogenomic RElationships) has been built for normalizing gene-drug and gene-disease relationships extracted from texts and is not suitable for representing ternary PGx relationships [2]. More recently, Samwald et al introduced the Pharmacogenomic Clinical Decision Support (or Genomic CDS) ontology, whose main goal is to propose consistent information about pharmacogenomic patient testing to the point of care, to guide physician decisions in clinical practice [12]. We have built PGxO by learning and adapting from these previous experiences.…”